Alnylam Pharmaceuticals (NASDAQ:ALNY) Shares Gap Down After Analyst Downgrade

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)’s share price gapped down prior to trading on Monday after Bank of America lowered their price target on the stock from $530.00 to $529.00. The stock had previously closed at $398.29, but opened at $377.82. Bank of America currently has a buy rating on the stock. Alnylam Pharmaceuticals shares last traded at $366.5260, with a volume of 552,543 shares trading hands.

ALNY has been the topic of a number of other reports. JPMorgan Chase & Co. cut their price target on shares of Alnylam Pharmaceuticals from $475.00 to $473.00 and set an “overweight” rating on the stock in a research note on Monday, October 13th. Morgan Stanley increased their target price on shares of Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the stock an “equal weight” rating in a report on Monday, October 6th. Jefferies Financial Group dropped their price target on shares of Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating for the company in a research note on Thursday, October 30th. Raymond James Financial reiterated an “outperform” rating and issued a $472.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday. Finally, Needham & Company LLC boosted their target price on Alnylam Pharmaceuticals from $520.00 to $529.00 and gave the stock a “buy” rating in a research note on Monday. Twenty-two analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $490.96.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, EVP Kevin Joseph Fitzgerald sold 12,128 shares of the firm’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $452.18, for a total transaction of $5,484,039.04. Following the transaction, the executive vice president directly owned 21,264 shares in the company, valued at approximately $9,615,155.52. This trade represents a 36.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Yvonne Greenstreet sold 15,650 shares of the company’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $453.69, for a total transaction of $7,100,248.50. Following the completion of the sale, the chief executive officer owned 65,409 shares of the company’s stock, valued at approximately $29,675,409.21. This trade represents a 19.31% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 37,778 shares of company stock valued at $17,096,988 in the last 90 days. 1.50% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals News Summary

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Alnylam unveiled its five‑year “Alnylam 2030” strategy, emphasizing leadership in ATTR amyloidosis, scaling the business and aiming for disciplined financial results — a clear roadmap for growth and commercialization that supports long‑term revenue upside. Alnylam Launches “Alnylam 2030” Strategy
• Positive Sentiment: Coverage and reporting (Benzinga, Benzinga summary) highlight the company’s five‑year roadmap and emphasis on TTR leadership and pipeline scale — reinforces management’s narrative and helps justify buy‑side conviction. Alnylam Lays Out 2030 Vision
• Positive Sentiment: Needham raised its price target (from $520 to $529) and kept a Buy rating, signaling continued analyst confidence and implying meaningful upside from current levels. Needham Price Target Raise
• Neutral Sentiment: AbbVie’s move into the PD‑1/VEGF area shifts competitive dynamics in oncology; BiopharmaDive notes Alnylam and Vertex are setting expectations — potential collaboration/competition could affect future opportunities but is not an immediate earnings driver. AbbVie Buys into PD‑1/VEGF Sweepstakes
• Neutral Sentiment: Sector and market reports (JPM conference coverage, DelveInsight market forecasts) point to broader industry trends (cardio market growth; big pharma pipeline news) that may indirectly affect investor rotation but don’t change Alnylam’s near‑term revenue picture. JPM26 Day 1 Coverage Atherosclerotic Cardiovascular Disease Market Forecast
• Neutral Sentiment: Bank of America trimmed its price target by $1 to $529 but kept a Buy rating — essentially unchanged consensus and still indicates sizable upside from current prices. BofA Price Target Note
• Negative Sentiment: Near‑term headwinds: technical/valuation and trading flow — the stock is under pressure versus its 50‑ and 200‑day moving averages, average volume is elevated and fundamentals (very high P/E, leverage metrics) leave the shares vulnerable to profit‑taking and rotation into other areas. These factors help explain today’s selloff despite supportive strategy and analyst views.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Groupama Asset Managment grew its position in shares of Alnylam Pharmaceuticals by 160.4% in the third quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock valued at $18,610,000 after purchasing an additional 2,483,697 shares during the last quarter. Norges Bank purchased a new stake in Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $662,837,000. Arrowstreet Capital Limited Partnership grew its holdings in Alnylam Pharmaceuticals by 698.8% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,355,609 shares of the biopharmaceutical company’s stock valued at $618,158,000 after buying an additional 1,185,909 shares during the last quarter. Qube Research & Technologies Ltd purchased a new position in Alnylam Pharmaceuticals during the third quarter worth $369,943,000. Finally, Holocene Advisors LP acquired a new position in shares of Alnylam Pharmaceuticals in the second quarter worth $194,616,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 4.45, a current ratio of 2.54 and a quick ratio of 2.49. The firm has a market capitalization of $49.00 billion, a PE ratio of 1,545.46 and a beta of 0.32. The company has a 50-day moving average price of $425.72 and a 200-day moving average price of $421.24.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.